Royalty Pharma Names Kenneth Sun as Senior Vice President and Head of Asia, Strengthening Its Global Expansion Strategy and Regional Presence Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of…
Zoetis moves to acquire the animal genomics unit of Neogen, strengthening its precision animal health capabilities. Zoetis Inc. the world’s leading animal health company, today announced it has entered into a definitive agreement with Neogen Corporation (NASDAQ: NEOG) (“Neogen”) to…
Roche’s fenebrutinib reaffirms potential as the sole BTK inhibitor for relapsing and primary progressive MS with positive FENhance 1 Phase III results. Roche announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary…
AbbVie Reports Positive Phase 3 Results for Subcutaneous SKYRIZI® in Crohn’s Disease AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) subcutaneous (SC) induction…
Genentech Announces Positive Phase III Results for Fenebrutinib in RMS, Paving the Way for Regulatory Submission Why is the search for effective treatments for multiple sclerosis (MS) more urgent than ever? Genentech, a member of the Roche Group, has announced…
New Combination Therapy Demonstrates 47% Reduction in Event-Free Survival Events Why is this a game-changer for bladder cancer treatment? Merck, a global leader in healthcare, has announced groundbreaking results from the Phase 3 KEYNOTE-B15 trial, which demonstrated that the combination…
Organon Presents Data on VTAMA Cream’s Impact on Sleep at AAAAI 2026 Annual Meeting How can we address the significant sleep disturbances that affect children with atopic dermatitis and their families? Organon a global healthcare company dedicated to delivering impactful…
Collaboration Aims to Overcome Delivery Challenges for Neurological Disorders Why has gene editing for Rett syndrome remained elusive despite its potential to reverse symptoms? Evox Therapeutics Ltd (Evox), a biotechnology company focused on developing innovative therapies for genetically driven neurodegenerative…
New Data Show Potential for Twice-Yearly Dosing, Enhancing Treatment Options for HIV Patients Why is the current landscape of HIV treatment ripe for innovation? ViiV Healthcare, a global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as…
Chemify and Sanacor Join Forces to Tackle Diabetic Cardiovascular Disease Why is the discovery of new therapies for diabetic cardiovascular disease so critical? Chemify, a deep-tech pioneer in Chemputation, and Sanacor Inc., a biotechnology company focused on mitochondrial dysfunction, have…
Ionis Poised for Continued Growth with Multiple Upcoming Therapeutic Launches Is the biotech industry ready for a new wave of transformative therapies? Ionis Pharmaceuticals, a leader in RNA-targeted therapies, reported robust financial results and significant pipeline advancements for the year…
Clinical-Stage Biotech Zura Bio Seeks to Raise Capital for Innovative Therapies In the competitive landscape of biotechnology, where innovation and capital are paramount, Zura Bio Limited (Nasdaq: ZURA) stands out as a company dedicated to developing novel and differentiated medicines…